Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Holding CYTK?
Track your performance easily
Cytokinetics (CYTK) Ownership Overview
0.72% Insiders
36.09% Mutual Funds
39.35% Other Institutional Investors
23.64% ETFs
0.20% Public Companies and
Individual Investors
The ownership structure of Cytokinetics (CYTK) stock is a mix of institutional, retail, and individual investors. Approximately 99.08% of the company’s stock is owned by Institutional Investors, 0.72% is owned by Insiders, and 0.20% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Nov 19, 2024 | Robert Blum President & Ceo,director | xxxxxxxxxxxxx | $252750 |
| Nov 13, 2024 | Fady Ibraham Malik Evp Research & Development | xxxxxxxxxxxxx | $370880 |
| Nov 04, 2024 | Robert Blum President & Ceo,director | xxxxxxxxxxxxx | $258150 |
| Oct 31, 2024 | Fady Ibraham Malik Evp Research & Development | xxxxxxxxxxxxx | $378930 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2024 | xxxxxxxxxxxxx | $465960 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $680275 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $715704 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $1280400 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 11,308,256 | Institution | 9.58% | 555,235,370 | |
| 10,100,475 | Institution | 8.56% | 495,933,323 | |
| 9,870,507 | Institution | 8.36% | 484,641,894 | |
| 4,308,116 | Institution | 3.65% | 211,528,496 | |
| 4,067,922 | Institution | 3.45% | 199,734,970 | |
| 2,252,713 | Institution | 1.91% | 110,608,208 | |
| 1,821,115 | Institution | 1.54% | 89,416,747 | |
| 1,598,152 | Institution | 1.35% | 78,469,263 | |
| 1,596,371 | Institution | 1.35% | 78,381,816 | |
| 1,497,941 | Institution | 1.27% | 73,548,903 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 9,870,507 | Institution | 8.36% | 484,641,894 | |
| 4,067,922 | Institution | 3.45% | 199,734,970 | |
| 2,252,713 | Institution | 1.91% | 110,608,208 | |
| 1,821,115 | Institution | 1.54% | 89,416,747 | |
| 1,598,152 | Institution | 1.35% | 78,469,263 | |
| 1,596,371 | Institution | 1.35% | 78,381,816 | |
| 1,497,941 | Institution | 1.27% | 73,548,903 | |
| 1,458,239 | Institution | 1.24% | 71,599,535 | |
| 1,297,216 | Institution | 1.10% | 63,693,306 | |
| 1,232,709 | Institution | 1.04% | 60,526,012 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,732,980 | Institution | 3.16% | 190,381,980 | |
| 3,743,479 | Institution | 3.17% | 183,804,819 | |
| 3,124,438 | Institution | 2.65% | 153,409,906 | |
| 2,950,999 | Institution | 2.50% | 150,500,949 | |
| 2,270,213 | Institution | 1.92% | 108,221,054 | |
| 1,755,460 | Institution | 1.49% | 89,528,460 | |
| 1,622,191 | Institution | 1.37% | 82,731,741 | |
| 1,013,162 | Institution | 0.86% | 49,746,254 | |
| 940,522 | Institution | 0.80% | 46,179,630 | |
| 786,826 | Institution | 0.67% | 38,633,157 |
FAQ
Who Owns Cytokinetics (CYTK)?
According to the latest TipRanks data, approximately 39.35% of the company's stock is held by institutional investors, 0.72% is held by insiders, and 0.20% is held by retail investors.
What percentage of Cytokinetics (CYTK) stock is held by institutional investors?
According to the latest TipRanks data, approximately 39.35% of Cytokinetics (CYTK) stock is held by institutional investors.
What percentage of Cytokinetics (CYTK) stock is held by retail investors?
According to the latest TipRanks data, approximately 0.20% of Cytokinetics (CYTK) stock is held by retail investors.
Who owns the most shares of Cytokinetics (CYTK)?
Vanguard owns the most shares of Cytokinetics (CYTK).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.